Colestipol
(GACQNVJDWUAPFY-UHFFFAOYSA-N)
Structure
- SMILES
- NCCNCCNCCNCCN.Cl
- Molecular Formula:
- C8H24ClN5
- Molecular Weight:
- 225.763
- Log P:
- 1.0479
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 6
- TPSA:
- 88.13
- CAS Number(s):
- 37296-80-3
Synonym(s)
1.
Colestipol
2.
Colestid
3.
Colestipol HCl
4.
Colestipol Hydrochloride
5.
U-26,597 A
6.
HCl, Colestipol
7.
Hydrochloride, Colestipol
8.
U 26,597 A
9.
U26,597 A
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 20 | US FAERS | |
| 2 | Product size issue | FAERS: 18 | US FAERS | |
| 3 | Product use in unapproved indication | FAERS: 14 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Drug ineffective for unapproved indication | FAERS: 12 | US FAERS | |
| 5 | Constipation | FAERS: 10 | US FAERS | |
| 6 | Choking | FAERS: 9 | US FAERS | |
| 7 | Flatulence | FAERS: 8 | US FAERS | |
| 8 | Malaise | FAERS: 8 | US FAERS | |
| 9 | Product use complaint | FAERS: 8 | US FAERS | |
| 10 | Product physical issue | FAERS: 7 | US FAERS | |
| 11 | Drug effective for unapproved indication | FAERS: 6 | US FAERS | |
| 12 | Foreign body in respiratory tract | FAERS: 5 | US FAERS | |
| 13 | Product use issue | FAERS: 5 | US FAERS | |
| 14 | Pruritus | FAERS: 5 | US FAERS | |
| 15 | Vomiting | FAERS: 5 | US FAERS | |
| 16 | Abdominal discomfort | FAERS: 4 | US FAERS | |
| 17 | Drug prescribing error | FAERS: 4 | US FAERS | |
| 18 | Intentional product misuse | FAERS: 4 | US FAERS | |
| 19 | Poor quality drug administered | FAERS: 4 | US FAERS | |
| 20 | Product difficult to swallow | FAERS: 4 | US FAERS | |
| 21 | Product quality issue | FAERS: 4 | US FAERS | |
| 22 | Blood alkaline phosphatase increased | FAERS: 3 | US FAERS | |
| 23 | Blood creatine phosphokinase increased | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 24 | Cerebrovascular accident | FAERS: 3 | US FAERS | |
| 25 | Dizziness | FAERS: 3 | US FAERS | |
| 26 | Dysphonia | FAERS: 3 | US FAERS | |
| 27 | Pain | FAERS: 3 | US FAERS | |
| 28 | Wrong technique in drug usage process | FAERS: 3 | US FAERS | |
| 29 | Wrong technique in product usage process | FAERS: 3 | US FAERS | |
| 30 | Alanine Aminotransferase Increased | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 31 | Asthenia | FAERS: 2 | US FAERS | |
| 32 | Colitis | FAERS: 2 | US FAERS | |
| 33 | Drug effect incomplete | FAERS: 2 | US FAERS | |
| 34 | Dyspepsia | FAERS: 2 | US FAERS | |
| 35 | Expired product administered | FAERS: 2 | US FAERS | |
| 36 | Feeling abnormal | FAERS: 2 | US FAERS | |
| 37 | Headache | FAERS: 2 | US FAERS | |
| 38 | Hypersensitivity | FAERS: 2 | US FAERS | |
| 39 | Intentional product use issue | FAERS: 2 | US FAERS | |
| 40 | Medication residue present | FAERS: 2 | US FAERS | |
| 41 | Myalgia | FAERS: 2 | US FAERS | |
| 42 | Nausea | FAERS: 2 | US FAERS | |
| 43 | Product substitution issue | FAERS: 2 | US FAERS | |
| 44 | Retching | FAERS: 2 | US FAERS | |
| 45 | Throat irritation | FAERS: 2 | US FAERS | |
| 46 | Urticaria | FAERS: 2 | US FAERS | |
| 47 | Abnormal sleep-related event | FAERS: 1 | US FAERS | |
| 48 | Allergic reaction to excipient | FAERS: 1 | US FAERS | |
| 49 | Arthralgia | FAERS: 1 | US FAERS | |
| 50 | Asthma | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 51 | Atrial Fibrillation | FAERS: 1 | US FAERS | |
| 52 | Bile acid malabsorption | FAERS: 1 | US FAERS | |
| 53 | Blood cholesterol increased | FAERS: 1 | US FAERS | |
| 54 | Breech Presentation | FAERS: 1 | US FAERS | |
| 55 | Burning sensation | FAERS: 1 | US FAERS | |
| 56 | Clostridium difficile infection | FAERS: 1 | US FAERS | |
| 57 | Dehydration | FAERS: 1 | US FAERS | |
| 58 | Dementia | FAERS: 1 | US FAERS | |
| 59 | Diabetes Mellitus | FAERS: 1 | US FAERS | |
| 60 | Discomfort | FAERS: 1 | US FAERS | |
| 61 | Disease Progression | FAERS: 1 | US FAERS | |
| 62 | Drug dose omission | FAERS: 1 | US FAERS | |
| 63 | Drug exposure during pregnancy | FAERS: 1 | US FAERS | |
| 64 | Dumping Syndrome | FAERS: 1 | US FAERS | |
| 65 | Duodenal Ulcer | FAERS: 1 | US FAERS | |
| 66 | Eructation | FAERS: 1 | US FAERS | |
| 67 | Fatigue | FAERS: 1 | US FAERS | |
| 68 | Fibromyalgia | FAERS: 1 | US FAERS | |
| 69 | Glaucoma | FAERS: 1 | US FAERS | |
| 70 | Hyporeflexia | FAERS: 1 | US FAERS | |
| 71 | Idiosyncratic drug reaction | FAERS: 1 | US FAERS | |
| 72 | Incorrect dose administered | FAERS: 1 | US FAERS | |
| 73 | Influenza | FAERS: 1 | US FAERS | |
| 74 | Intestinal Obstruction | FAERS: 1 | US FAERS | |
| 75 | Joint swelling | FAERS: 1 | US FAERS | |
| 76 | Lipoma | FAERS: 1 | US FAERS | |
| 77 | Medication residue | FAERS: 1 | US FAERS | |
| 78 | Musculoskeletal Pain | FAERS: 1 | US FAERS | |
| 79 | Myocardial Infarction | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 80 | Nasopharyngitis | FAERS: 1 | US FAERS | |
| 81 | Osteopenia | FAERS: 1 | US FAERS | |
| 82 | Osteoporosis | FAERS: 1 | US FAERS | |
| 83 | Peripheral swelling | FAERS: 1 | US FAERS | |
| 84 | Pharmaceutical product complaint | FAERS: 1 | US FAERS | |
| 85 | Pneumonia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 86 | Poor quality product administered | FAERS: 1 | US FAERS | |
| 87 | Pregnancy | FAERS: 1 | US FAERS | |
| 88 | Product taste abnormal | FAERS: 1 | US FAERS | |
| 89 | Productive Cough | FAERS: 1 | US FAERS | |
| 90 | Reaction to excipient | FAERS: 1 | US FAERS | |
| 91 | Respiratory distress | FAERS: 1 | US FAERS | |
| 92 | Restless Legs Syndrome | FAERS: 1 | US FAERS | |
| 93 | Rheumatoid Arthritis | FAERS: 1 | US FAERS | |
| 94 | Senile dementia | FAERS: 1 | US FAERS | |
| 95 | Thermal burn | FAERS: 1 | US FAERS | |
| 96 | Thirst | FAERS: 1 | US FAERS | |
| 97 | Tinnitus | FAERS: 1 | US FAERS | |
| 98 | Transaminases increased | FAERS: 1 | US FAERS | |
| 99 | Ulcer | FAERS: 1 | US FAERS | |
| 100 | Vascular rupture | FAERS: 1 | US FAERS | |
| 101 | Weight decreased | FAERS: 1 | US FAERS | |
| 102 | Wheezing | FAERS: 1 | US FAERS | |
| 103 | treatment failure | FAERS: 1 | US FAERS | |
| 104 | Aspartate Aminotransferase Increased | Canada Vigilance: 1 | Canada Vigilance | |
| 105 | Dysgeusia | Canada Vigilance: 1 | Canada Vigilance | |
| 106 | Stomatitis | Canada Vigilance: 1 | Canada Vigilance | |
| 107 | Therapeutic product effect decreased | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.